About this Research Topic
Gliomas represent the most predominant and aggressive malignancies of the central nervous system, presenting substantial challenges due to their complex biology and adaptive resistance mechanisms. These tumors are notorious for their poor prognosis and limited treatment options, necessitating continuous exploration for effective therapeutic agents and strategies. Current treatments often fall short in overcoming the sophisticated defense mechanisms inherent to gliomas, underscoring the urgent need for innovation in this field.
The primary aim of this Research Topic is to address the formidable treatment challenges posed by gliomas through the discovery and development of novel therapeutic agents and strategies. Recent advancements in glioma pharmacotherapy have opened new avenues for combating treatment resistance and improving patient outcomes. By exploring cutting-edge research in drug discovery, translational studies, and combination therapies, we aspire to enhance the efficacy of glioma treatments. We seek to highlight works that delve into mechanistic insights of resistance, present innovative drug delivery systems, and employ computational approaches to identify and validate new targets. This collective effort endeavors to fortify the scientific community’s arsenal against gliomas and pave the way for breakthroughs in treatment.
This RT encompasses a wide array of themes pivotal to advancing glioma pharmacotherapy. We invite submissions of original research articles, clinical trial data, and comprehensive reviews that cover, but are not limited to:
• Discovery and pre-clinical development of novel drugs targeting glioma.
• Translational research bridging pre-clinical findings with clinical trials.
• Mechanistic insights into glioma resistance to current therapies.
• Innovative combination therapies to enhance efficacy and reduce resistance.
• Development and optimization of drug delivery systems specifically tailored for glioma therapy.
• Computational and systems biology approaches to identify and validate new drug targets.
Our goal is to foster a multidisciplinary dialogue among researchers, encouraging collaborations that could lead to significant breakthroughs in glioma treatment.
The primary aim of this Research Topic is to address the formidable treatment challenges posed by gliomas through the discovery and development of novel therapeutic agents and strategies. Recent advancements in glioma pharmacotherapy have opened new avenues for combating treatment resistance and improving patient outcomes. By exploring cutting-edge research in drug discovery, translational studies, and combination therapies, we aspire to enhance the efficacy of glioma treatments. We seek to highlight works that delve into mechanistic insights of resistance, present innovative drug delivery systems, and employ computational approaches to identify and validate new targets. This collective effort endeavors to fortify the scientific community’s arsenal against gliomas and pave the way for breakthroughs in treatment.
This RT encompasses a wide array of themes pivotal to advancing glioma pharmacotherapy. We invite submissions of original research articles, clinical trial data, and comprehensive reviews that cover, but are not limited to:
• Discovery and pre-clinical development of novel drugs targeting glioma.
• Translational research bridging pre-clinical findings with clinical trials.
• Mechanistic insights into glioma resistance to current therapies.
• Innovative combination therapies to enhance efficacy and reduce resistance.
• Development and optimization of drug delivery systems specifically tailored for glioma therapy.
• Computational and systems biology approaches to identify and validate new drug targets.
Our goal is to foster a multidisciplinary dialogue among researchers, encouraging collaborations that could lead to significant breakthroughs in glioma treatment.
Keywords: Glioma, Treatment Resistance, Pharmacological Target, Novel Drug
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
